Martin Holst Lange, Novo Nordisks Chief Scientific Officer, put it bluntly: Wegovy is now uniquely positioned as the first and only GLP1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide Living with liver disease will still require lifestyle changes
Clinical data suggests Wegovy causes slightly lower rates of gastrointestinal side effects compared to Zepbound
Selecting the right protein shake requires consideration of protein content, digestibility, sugar levels, and individual tolerance to support lean body mass preservation during semaglutide treatment
Together, they address tissue repair from multiple angles
They provide ongoing monitoring of your health and progress, adjusting your treatment plan as necessary